OGN * Stock Overview
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 0/6 |
| Dividends | 3/6 |
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$299.00 |
| 52 Week High | US$425.00 |
| 52 Week Low | US$189.00 |
| Beta | 0.79 |
| 1 Month Change | 7.17% |
| 3 Month Change | n/a |
| 1 Year Change | -29.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| OGN * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | 1.3% |
| 1Y | -29.5% | -20.6% | 1.6% |
Return vs Industry: OGN * underperformed the MX Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: OGN * underperformed the MX Market which returned 2.6% over the past year.
Price Volatility
| OGN * volatility | |
|---|---|
| OGN * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 1.9% |
Stable Share Price: OGN * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OGN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| OGN * fundamental statistics | |
|---|---|
| Market cap | Mex$81.04b |
| Earnings (TTM) | Mex$17.61b |
| Revenue (TTM) | Mex$107.79b |
4.6x
P/E Ratio0.8x
P/S RatioIs OGN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGN * income statement (TTM) | |
|---|---|
| Revenue | US$6.26b |
| Cost of Revenue | US$2.52b |
| Gross Profit | US$3.75b |
| Other Expenses | US$2.73b |
| Earnings | US$1.02b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.00 |
| Gross Margin | 59.84% |
| Net Profit Margin | 16.33% |
| Debt/Equity Ratio | -12,514.3% |
How did OGN * perform over the long term?
See historical performance and comparison